亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Preconditioned Human Mesenchymal Stem Cells (hMSCs) for Musculoskeletal Tissue Repair

技術優勢: Improved cell survival and engraftment Able to manipulate biophysical properties of spheroid-hydrogel system

詳細技術說明: Bone defects that extend beyond a critical size are associated with impaired native healing due to age or disease. Approximately 10% of patients with bone defects do not have sufficient bone repair processes, leading to fractures, infections, and other comorbidities. Human mesenchymal stem cell (hMSC)-based therapies have high therapeutic potential for such bone repair but have limited efficacy in vivo: calcification of surrounding tissue occurs due to limited oxygen supply and decreased nutrient exchange. Researchers at the University of California, Davis have developed a novel treatment for bone repair that offers an optimized survival rate of human mesenchymal stem cells and engraftment once implanted into a bone defect. The method incorporates pre-treatment of the cells combined with an engineered cell carrier system, resulting in synergistically improved bone healing compared to existing monolayer cell therapies and spheroid formation methods. This method has successfully exhibited higher cell density, osteogenic potential and increased secretion of proangiogenic factors in vitro with significantly more bone healing in critical-sized femoral segment defects in rats in vivo. This method represents a simple approach for enhanced, long-term therapeutic bone healing.

*Abstract: Researchers at the University of California, Davis have developed a preconditioning treatment and delivery method for human mesenchymal stem cell (hMSC) for enhanced bone healing.

*Principal Investigation: Name: Steve Ho
Department:

Name: Kent Leach
Department:

欲了解更多信息，請點擊這裡